Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Hess, Georg [1 ]
Kang, Lisa [2 ]
Moran, Padraig J. [3 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Dublin, PA, Ireland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1165 / 1165
页数：1
相关论文
共 50 条
  • [41] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [42] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [43] Efficacy and Safety Of Treatments For Relapsed Or Refractory Mantle Cell Lymphoma (MCL): Results Of a Systematic Literature Review
    Njue, Annete
    Trask, Peter C.
    Colosia, Ann
    Olivares, Robert
    Khan, Shahnaz
    Abbe, Adeline
    Police, Rachel Lee
    Wang, Jianmin
    Sherrill, Elizabeth
    Kaye, James A.
    Awan, Farrukh T.
    BLOOD, 2013, 122 (21)
  • [44] Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator's Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Romaguera, Jorge
    Coiffier, Bertrand
    Crump, Michael
    Herbrecht, Raoul
    Verhoef, Gregor
    Hanushevsky, Orysia
    Strahs, Andrew
    Hewes, Becker
    Berkenblit, Anna
    Hess, Georg
    BLOOD, 2008, 112 (11) : 553 - 553
  • [45] Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma.
    Bair, A.
    Hess, G.
    Boni, J.
    Offner, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Management of relapsed/refractory mantle cell lymphoma
    Alzahrani, Musa
    Villa, Diego
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1044 - 1054
  • [47] TemsirolimusIn Relapsed and/or Refractory Mantle Cell Lymphoma
    Sheridan M. Hoy
    Kate McKeage
    Drugs, 2010, 70 : 1819 - 1829
  • [48] Dismantling relapsed/refractory mantle cell lymphoma
    Ryan, Christine E.
    Kumar, Anita
    BLOOD REVIEWS, 2024, 67
  • [49] Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
    Kim, T. M.
    Taszner, M.
    Novelli, S.
    Cho, S. -G
    Villasboas, J. C.
    Merli, M.
    Jimenez-Ubieto, A.
    Tessoulin, B.
    Poon, L. M.
    Tucker, D.
    Walewski, J.
    Yi, S.
    Song, Y.
    Chong, G.
    Bachy, E.
    Guidez, S.
    Alonso, A.
    Jagadeesh, D.
    Zhang, W.
    Magnano, L.
    Iskierka-Jazdzewska, E.
    Tani, M.
    Shen, B.
    Uppala, A.
    Zhu, M.
    Shariff, S.
    Brouwer-Visser, J.
    Chaudhry, A.
    Mohamed, H.
    Ambati, S.
    Luminari, S.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1039 - 1047
  • [50] TREATMENT OF PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA WITH TEMSIROLIMUS: ADVERSE EVENT PROFILES OF HIGH AND LOW DOSE REGIMENS ARE SIMILAR
    Herbrecht, R.
    Romaguera, J.
    Verhoef, G.
    Crump, M.
    Coiffier, B.
    Strahs, A.
    Galand, L.
    Binlich, F.
    Hewes, B.
    Hess, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 229 - 229
12345